Clinical Trial Update: Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating suprachoroidally administered CLS-AX for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• CLS-AX

Snippet

Sponsor: Clearside Biomedical, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED